Real-World Studies
Real-World Adverse Events and Operational Impact of T-Cell Engager Therapy in Community Oncology
Fernandes et alCanadian Oncology Nursing Journal
T-cell engager (TCE) therapies represent an evolving class of immunotherapies for hematologic malignancies and small-cell lung cancer, though their clinical utility is frequently complicated by cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). A retrospective chart review evaluated 30 patients who received TCE therapy between and at the Osler Oncology Program at Brampton Civic Hospital to assess the clinical frequency, severity, onset timing, and operational footprint of these toxicities in a community oncology setting. Adverse events were graded using the American Society for Transplantation and Cellular Therapy (ASTCT) consensus criteria.
The analysis revealed that CRS developed in 77% (23/30) of patients. The majority of CRS presentations were mild, with Grade 1 events accounting for 70% of all CRS cases. The timing of onset was closely tied to early administration, with most episodes transpiring within 24 hours of ramp-up dosing and primarily after Dose 1. Early intervention using tocilizumab for Grade 1 CRS appeared to mitigate progression to higher toxicity grades.
ICANS was documented in 27% (8/30) of patients, including one Grade 4 event. Notably, 75% of all ICANS occurrences arose in individuals who had also experienced CRS. Operationally, the mean cumulative inpatient length of stay across the ramp-up dosing schedule was 11.4 days, characterized by a substantial reduction over consecutive doses—averaging 7.2 days during the initial visit and decreasing to 1.6 days by Dose 3. These findings confirm the operational feasibility of delivering TCE therapy in community hospital programs while highlighting the necessity of standardized nursing assessment protocols, early toxicity monitoring, and potential risk-stratified outpatient transition models for selected candidates.
Key Takeaways
- Cytokine release syndrome occurred in 77% (23/30) of patients receiving T-cell engager therapy, presenting predominantly as Grade 1 events (70% of CRS cases) within 24 hours of ramp-up dosing and primarily following Dose 1.
- Immune effector cell-associated neurotoxicity syndrome was observed in 27% (8/30) of patients, including one Grade 4 event, with 75% of neurotoxicity cases occurring in patients who also experienced CRS.
- Mean total length of stay during ramp-up dosing was 11.4 days, falling from 7.2 days for the initial visit to 1.6 days for Dose 3, while early intervention with tocilizumab for Grade 1 CRS appeared to reduce progression to higher-grade toxicity.
Read the original sourceCanadian Oncology Nursing Journal
